Collagen-VI supplementation by cell transplantation improves muscle regeneration in Ullrich congenital muscular dystrophy model mice.
COL6 related disease
Induced pluripotent stem cells
Mesenchymal stromal cells
Skeletal muscle regeneration
Ullrich congenital muscular dystrophy
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
09 08 2021
09 08 2021
Historique:
received:
06
05
2021
accepted:
13
07
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
26
8
2021
Statut:
epublish
Résumé
Mesenchymal stromal cells (MSCs) function as supportive cells on skeletal muscle homeostasis through several secretory factors including type 6 collagen (COL6). Several mutations of COL6A1, 2, and 3 genes cause Ullrich congenital muscular dystrophy (UCMD). Skeletal muscle regeneration deficiency has been reported as a characteristic phenotype in muscle biopsy samples of human UCMD patients and UCMD model mice. However, little is known about the COL6-dependent mechanism for the occurrence and progression of the deficiency. The purpose of this study was to clarify the pathological mechanism of UCMD by supplementing COL6 through cell transplantation. To test whether COL6 supplementation has a therapeutic effect for UCMD, in vivo and in vitro experiments were conducted using four types of MSCs: (1) healthy donors derived-primary MSCs (pMSCs), (2) MSCs derived from healthy donor induced pluripotent stem cell (iMSCs), (3) COL6-knockout iMSCs (COL6KO-iMSCs), and (4) UCMD patient-derived iMSCs (UCMD-iMSCs). All four MSC types could engraft for at least 12 weeks when transplanted into the tibialis anterior muscles of immunodeficient UCMD model (Col6a1KO) mice. COL6 protein was restored by the MSC transplantation if the MSCs were not COL6-deficient (types 1 and 2). Moreover, muscle regeneration and maturation in Col6a1KO mice were promoted with the transplantation of the COL6-producing MSCs only in the region supplemented with COL6. Skeletal muscle satellite cells derived from UCMD model mice (Col6a1KO-MuSCs) co-cultured with type 1 or 2 MSCs showed improved proliferation, differentiation, and maturation, whereas those co-cultured with type 3 or 4 MSCs did not. These findings indicate that COL6 supplementation improves muscle regeneration and maturation in UCMD model mice.
Sections du résumé
BACKGROUND
Mesenchymal stromal cells (MSCs) function as supportive cells on skeletal muscle homeostasis through several secretory factors including type 6 collagen (COL6). Several mutations of COL6A1, 2, and 3 genes cause Ullrich congenital muscular dystrophy (UCMD). Skeletal muscle regeneration deficiency has been reported as a characteristic phenotype in muscle biopsy samples of human UCMD patients and UCMD model mice. However, little is known about the COL6-dependent mechanism for the occurrence and progression of the deficiency. The purpose of this study was to clarify the pathological mechanism of UCMD by supplementing COL6 through cell transplantation.
METHODS
To test whether COL6 supplementation has a therapeutic effect for UCMD, in vivo and in vitro experiments were conducted using four types of MSCs: (1) healthy donors derived-primary MSCs (pMSCs), (2) MSCs derived from healthy donor induced pluripotent stem cell (iMSCs), (3) COL6-knockout iMSCs (COL6KO-iMSCs), and (4) UCMD patient-derived iMSCs (UCMD-iMSCs).
RESULTS
All four MSC types could engraft for at least 12 weeks when transplanted into the tibialis anterior muscles of immunodeficient UCMD model (Col6a1KO) mice. COL6 protein was restored by the MSC transplantation if the MSCs were not COL6-deficient (types 1 and 2). Moreover, muscle regeneration and maturation in Col6a1KO mice were promoted with the transplantation of the COL6-producing MSCs only in the region supplemented with COL6. Skeletal muscle satellite cells derived from UCMD model mice (Col6a1KO-MuSCs) co-cultured with type 1 or 2 MSCs showed improved proliferation, differentiation, and maturation, whereas those co-cultured with type 3 or 4 MSCs did not.
CONCLUSIONS
These findings indicate that COL6 supplementation improves muscle regeneration and maturation in UCMD model mice.
Identifiants
pubmed: 34372931
doi: 10.1186/s13287-021-02514-3
pii: 10.1186/s13287-021-02514-3
pmc: PMC8351132
doi:
Substances chimiques
Collagen Type VI
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
446Informations de copyright
© 2021. The Author(s).
Références
J Biol Chem. 2015 Sep 11;290(37):22771-81
pubmed: 26178374
Mech Ageing Dev. 2012 May;133(5):215-25
pubmed: 22738657
J Cell Sci. 2015 Oct 1;128(19):3525-31
pubmed: 26377767
J Cell Sci. 2011 Nov 1;124(Pt 21):3654-64
pubmed: 22045730
J Biol Chem. 2002 Feb 1;277(5):3242-6
pubmed: 11711546
Cold Spring Harb Perspect Biol. 2013 May 01;5(5):a011387
pubmed: 23580791
J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):280-7
pubmed: 24938411
Matrix Biol. 2001 Nov;20(7):475-86
pubmed: 11691587
PLoS One. 2014 Dec 02;9(12):e112291
pubmed: 25464501
Am J Med Genet A. 2005 Jan 30;132A(3):296-301
pubmed: 15690374
Arch Pharm Res. 2009 Jan;32(1):117-26
pubmed: 19183884
J Exp Med. 2013 Jun 3;210(6):1137-51
pubmed: 23712428
Autophagy. 2015;11(12):2142-52
pubmed: 26565691
Nat Genet. 2003 Dec;35(4):367-71
pubmed: 14625552
Neuromuscul Disord. 2007 Aug;17(8):587-96
pubmed: 17588753
Essays Biochem. 2019 Sep 13;63(3):297-312
pubmed: 31387942
Nat Rev Neurol. 2011 Jun 21;7(7):379-90
pubmed: 21691338
J Biol Chem. 2014 Apr 11;289(15):10293-10307
pubmed: 24563484
Cancer Res. 2004 Feb 1;64(3):817-20
pubmed: 14871805
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7516-21
pubmed: 11381124
Cell Commun Signal. 2011 May 14;9:12
pubmed: 21569606
Nat Cell Biol. 2010 Feb;12(2):143-52
pubmed: 20081842
Neurology. 2007 Sep 4;69(10):1035-42
pubmed: 17785673
Connect Tissue Res. 2013;54(6):345-50
pubmed: 23869615
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11796-801
pubmed: 18697938
Arthritis Rheum. 1997 Feb;40(2):270-6
pubmed: 9041938
Ann Neurol. 2001 Aug;50(2):261-5
pubmed: 11506412
Matrix Biol. 2018 Oct;71-72:348-367
pubmed: 29277723
EBioMedicine. 2017 Feb;15:193-202
pubmed: 28043812
Matrix Biol. 2009 Oct;28(8):480-9
pubmed: 19698785
Stem Cell Reports. 2016 Aug 9;7(2):263-78
pubmed: 27509136
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Biochem Biophys Res Commun. 1993 Mar 31;191(3):1230-6
pubmed: 8466500
J Biol Chem. 1996 Oct 25;271(43):26884-91
pubmed: 8900172
Hum Mol Genet. 2010 Jun 15;19(12):2433-44
pubmed: 20338942
Nat Commun. 2013;4:1964
pubmed: 23743995
Cell Rep. 2019 May 14;27(7):2029-2035.e5
pubmed: 31091443
J Biol Chem. 2001 Dec 21;276(51):48206-12
pubmed: 11572855
Exp Cell Res. 1992 Jun;200(2):490-9
pubmed: 1572410
Matrix Biol. 2007 Apr;26(3):146-55
pubmed: 17141492
Br J Pharmacol. 2009 Jul;157(6):1045-52
pubmed: 19519726
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
Stem Cell Res Ther. 2014 Feb 12;5(1):21
pubmed: 24522088
Exp Cell Res. 2004 Aug 1;298(1):305-15
pubmed: 15242785
Invest Ophthalmol Vis Sci. 1998 Feb;39(2):263-75
pubmed: 9477982
Ann Neurol. 2001 Apr;49(4):544
pubmed: 11310637
Cell Stem Cell. 2019 Apr 4;24(4):566-578.e7
pubmed: 30853558
Nat Med. 2010 Nov;16(11):1313-20
pubmed: 21037586
Hum Mol Genet. 2014 Oct 15;23(20):5353-63
pubmed: 24852368
Autophagy. 2016 Dec;12(12):2484-2495
pubmed: 27656840
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5225-9
pubmed: 18362356
Exp Cell Res. 1993 May;206(1):167-76
pubmed: 8387021
Nat Commun. 2017 Jun 12;8:15861
pubmed: 28604699
Neuromuscul Disord. 2003 May;13(4):310-6
pubmed: 12868500